Court Of Appeal Makes Decision Following Ruling That Nice Process On Anti-Dementia Medicines Unfair, UK

Eisai Limited, the licence holder of Aricept (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, announced today that the Court of Appeal has released its decision on the consequential issues arising from Court of Appeal's recent ruling that the process by which the National Institute for Health and Clinical Excellence (NICE) decided to restrict anti-dementia medicines for newly diagnosed patients with mild Alzheimer's disease was procedurally unfair. ...

Write comment to this article:

Subject:

Name:

email or site:

Code: